Skip to main content

Advertisement

Table 5 Clinical toxoplasmosis in congenitally-infected children in Colombia

From: An overview of seventy years of research (1944 – 2014) on toxoplasmosis in Colombia, South America

Reference Location Type of sample No. tested Infected (%) Sex (%) Deaths (%) Neurological symptoms and signs (%) Ocular symptoms and signs (%) Hepato-splenomegaly (%) Prematurity (%)
1981[30] Cali Referred cases (1955–1975), confirmed by necropsy (21 cases) or with serological studies 44 NA Male 25 (56.8) 21 (47.7) Microcephaly and cerebral calcifications: 30 (68.1) 25 (56.8) 27 (62.5) 8/16 (50.0)
1983[50] Medellin Referred cases confirmed by IFAT test 27 NA Male 17 (63.0) NR Microcephaly: 20 (74.0) Neurological psicomotor deficit: 22 (81.5) Electroencephalogram changes: 8/14 (57.0) Strabismus: 9 (33.0) Cataract: 1 (3.7) Chorioretinitis 11(40.7) 8 (29.0) 5 (18.5)
1997[21] Quindío Children prenatal screening 15 1/15 (6.7) Female NR NR Chorioretinitis (6.7) NR NR
2000[51] Bogota Armenia Referred cases confirmed by IFAT and ISAGA test 27 NA NR 1 (3.7) Calcification, hydrocephaly or microcephaly: 12 (44.4) Chorioretinitis 11 (40.7) 16 (59.0) 5 (18.5)
2005[52] Armenia Children prenatal or newborn screening 26 (17 by screening and 11 symptomatic) NA NR 2 screened <6 mo. of age (11.7%) 1 of 11 symptomatic (9%). 17 screened 4 of 11 symptomatic (36%) 13 screened 4 symptomatic (30%) 26 screened 7 symptomatic (26.9%) NR
2006[53] Quindío Newborn screening in referral hospital 200 1/200 (0.5) Female 1 (Respiratory distress syndrome) NR NR NR NR
2007[54] Quindío Newborn screening in community hospitals 322 2/322 (0.5) NR NR NR NR NR NR
2011[10] Armenia Barranquilla Riohacha Cucuta Bogota BucaramangaFlorencia National multicentric newborn screening 15,333 218 (1.4) by criteria for confirmation assays (109; 50% by confirmatory assays; 15 (13.7%) by congenital infection and 3/15 newborns with prenatal treatment NR 3/15 (20.0) 4/15 (26.6) calcifications; 1/15 (6.6) hydrocephaly 3/15 (20.0) chorioretinitis 1/15 (6.6) splenomegaly 1/15 (6.6)
  1. NA: not applicable; NR: not registered.